BTIG Research Issues Pessimistic Forecast for Avalo Therapeutics (NASDAQ:AVTX) Stock Price

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) had its target price lowered by equities research analysts at BTIG Research to $10.00 in a research note issued on Friday, Benzinga reports. The firm currently has a "buy" rating on the stock. BTIG Research's target price would suggest a potential upside of 34.23% from the company's current price.

Several other equities research analysts have also commented on the company. HC Wainwright reiterated a "neutral" rating on shares of Avalo Therapeutics in a research note on Friday. Guggenheim reissued a "neutral" rating on shares of Avalo Therapeutics in a report on Friday. Leerink Partners began coverage on Avalo Therapeutics in a research report on Monday, July 6th. They issued an "outperform" rating and a $38.00 target price on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Avalo Therapeutics in a research note on Wednesday, September 16th. Finally, Weiss Ratings raised Avalo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Avalo Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $39.10.

Avalo Therapeutics Stock Down 39.2%

AVTX stock opened at $7.45 on Friday. The stock has a market capitalization of $399.54 million, a P/E ratio of -1.70 and a beta of 0.68. The firm has a 50-day simple moving average of $16.30 and a 200-day simple moving average of $16.67. Avalo Therapeutics has a 52 week low of $6.85 and a 52 week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, analysts expect that Avalo Therapeutics will post -2.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Christopher Sullivan sold 12,394 shares of the company's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the completion of the sale, the chief financial officer owned 39,900 shares of the company's stock, valued at approximately $651,567. This represents a 23.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 24,258 shares of company stock worth $415,434 in the last quarter. Insiders own 4.46% of the company's stock.

Institutional Trading of Avalo Therapeutics

Several large investors have recently added to or reduced their stakes in AVTX. Braidwell LP purchased a new stake in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $30,107,000. Seven Fleet Capital Management LP grew its holdings in shares of Avalo Therapeutics by 806.0% during the 1st quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company's stock worth $8,568,000 after purchasing an additional 510,540 shares during the period. Squarepoint Ops LLC increased its position in shares of Avalo Therapeutics by 624.9% during the 2nd quarter. Squarepoint Ops LLC now owns 589,245 shares of the company's stock worth $10,889,000 after purchasing an additional 507,960 shares during the last quarter. DV Trading LLC acquired a new stake in shares of Avalo Therapeutics during the 1st quarter worth about $5,376,000. Finally, Affinity Asset Advisors LLC increased its position in shares of Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company's stock worth $20,019,000 after purchasing an additional 289,786 shares during the last quarter. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics News Summary

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: BTIG Research maintained a Buy rating while reducing its price target to $10 from $58. The revised target still implies meaningful upside from the referenced $7.45 share price. BTIG Research rating information
• Positive Sentiment: Wedbush cut its price target to $22 from $34 but retained an Outperform rating, indicating continued confidence in Avalo’s longer-term opportunity despite near-term competitive concerns. Wedbush adjusts Avalo price target
• Neutral Sentiment: Guggenheim reaffirmed its Neutral rating, while HC Wainwright separately reaffirmed Neutral in another research update. These actions suggest limited conviction following the recent decline. Guggenheim rating information HC Wainwright rating information
• Neutral Sentiment: Trading in AVTX was temporarily halted under a volatility-related LULD pause, highlighting elevated short-term trading risk but providing no fundamental update.
• Negative Sentiment: HC Wainwright downgraded Avalo from Buy to Neutral, removing a bullish analyst stance. HC Wainwright downgrades Avalo
• Negative Sentiment: Phase III results from AbbVie in hidradenitis suppurativa appear to have raised the competitive bar for Avalo’s AVTX-009 program, weighing on the stock and contributing to broader analyst price-target reductions. AbbVie phase III data subdue Avalo shares

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company's research and development programs are intended to address conditions with significant unmet medical needs.

Avalo's lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.